Graney & King’s Biogen BIIB Stock Holding History

Graney & King’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.9K	Hold	106	–	–	0.01%	206
2026 Q1	$19.4K	Hold	106	–	–	0.01%	204
2025 Q4	$18.7K	Hold	106	–	–	0.01%	203
2025 Q3	$14.8K	Hold	106	–	–	0.01%	203
2025 Q2	$13.3K	Hold	106	–	–	0.01%	202
2025 Q1	$14.5K	Buy	+106	New	+$15.2K	0.01%	196

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Graney & King's BIIB Position: Q2 2026 in Review

Graney & King held its Biogen (BIIB) position steady in Q2 2026 at 106 shares worth $22.9K. The position accounts for 0.01% of the portfolio, ranked #206.

Graney & King first reported a position in BIIB in Q1 2025 and has held it in 6 quarters since. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Graney & King held 106 shares of Biogen worth $22.9K as of Q2 2026.
Graney & King left its Biogen share count unchanged in Q2 2026.
Biogen made up 0.01% of Graney & King's portfolio in Q2 2026, its #206 holding.
Graney & King first reported a position in Biogen in Q1 2025 and has held it in 6 quarters since.
1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Graney & King's 13F filing for Q2 2026, filed 7 Aug 2026.